ZYME

Zymeworks Inc. NASDAQ

Healthcare ·Biotechnology ·CA · zymeworks.com

$26.78

Mkt Cap $2.0B

52w Low $10.86 84.3% of range 52w High $29.75

50d MA $25.40 200d MA $21.05

P/E (TTM) -24.6x

EV/EBITDA 0.3x

P/B 7.5x

Debt/Equity 0.1x

ROE -30.2%

P/FCF -57.5x

RSI (14) —

ATR (14) —

Beta 1.20

50d MA $25.40

200d MA $21.05

Avg Volume 639.5K

About

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparato…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 2, 2026	AMC	-0.35	-0.55	-57.1%	23.31	+2.1%	+4.9%	+8.2%	+6.4%	+3.3%	+4.0%	—
Nov 6, 2025	AMC	-0.30	-0.26	+13.3%	17.90	-5.0%	-8.0%	+0.8%	+9.9%	+8.2%	+3.4%	—
Aug 7, 2025	AMC	-0.52	0.03	+105.8%	12.16	+2.3%	-1.2%	+2.3%	+7.1%	+14.6%	+17.6%	—
May 8, 2025	AMC	-0.45	-0.30	+33.3%	11.32	+0.5%	-0.1%	+6.2%	+2.6%	-0.6%	+1.9%	—
Mar 5, 2025	AMC	0.01	-0.31	-3200.0%	13.18	-5.6%	-8.0%	-9.0%	-15.8%	-11.2%	-6.8%	—
Oct 31, 2024	AMC	-0.40	-0.39	+2.5%	13.70	-6.8%	-3.1%	+7.7%	+7.0%	+13.9%	+22.4%	—
Aug 1, 2024	AMC	-0.42	-0.49	-17.4%	10.11	+4.8%	+0.9%	-1.1%	+0.4%	-2.8%	+0.9%	—
May 2, 2024	AMC	-0.31	-0.42	-35.5%	9.00	-1.8%	+2.2%	+0.7%	+1.3%	+0.7%	+2.6%	—
Mar 6, 2024	AMC	-0.39	-0.20	+48.7%	12.23	-6.9%	-6.5%	-6.5%	-9.6%	-11.6%	-12.1%	—
Nov 7, 2023	AMC	-0.55	-0.41	+25.5%	7.37	+2.6%	-3.7%	-5.7%	-1.1%	-1.4%	+3.5%	—
Aug 10, 2023	AMC	-0.51	-0.76	-49.0%	7.76	-9.8%	-7.6%	-3.5%	-4.4%	-6.3%	-5.3%	—
May 8, 2023	AMC	-0.64	-0.37	+42.2%	8.76	+11.8%	+12.8%	+10.6%	+13.9%	+12.6%	+12.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 9	Evercore ISI	Maintains	Outperform → Outperform	—	$24.08	$23.88	-0.8%	+0.7%	+5.7%	+4.4%	-3.5%	-5.0%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.80	$25.09	+1.2%	-2.9%	-2.2%	+2.7%	+1.4%	-6.3%
Mar 3	Stifel	Maintains	Buy → Buy	—	$23.31	$23.80	+2.1%	+4.9%	+8.2%	+6.4%	+3.3%	+4.0%
Mar 3	Leerink Partners	Maintains	Outperform → Outperform	—	$23.31	$23.80	+2.1%	+4.9%	+8.2%	+6.4%	+3.3%	+4.0%
Dec 12	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$24.94	$26.28	+5.4%	+2.2%	+4.1%	+3.6%	+2.6%	+5.9%
Nov 21	B. Riley Securities	Maintains	Buy → Buy	—	$23.82	$23.82	+0.0%	+0.8%	+4.9%	+9.9%	+14.7%	+12.1%
Nov 19	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$22.99	$23.01	+0.1%	-1.7%	+3.6%	+4.5%	+8.7%	+13.9%
Nov 19	Stifel	Maintains	Buy → Buy	—	$22.99	$23.01	+0.1%	-1.7%	+3.6%	+4.5%	+8.7%	+13.9%
Nov 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.90	$24.28	+1.6%	-3.8%	-5.4%	-0.3%	+0.5%	+4.6%
Nov 7	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$17.90	$17.01	-5.0%	-8.0%	+0.8%	+9.9%	+8.2%	+3.4%
Oct 16	JP Morgan	Maintains	Overweight → Overweight	—	$18.62	$18.94	+1.7%	-0.4%	-1.2%	-1.6%	-3.7%	-5.1%
Oct 14	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$18.11	$18.96	+4.7%	+0.7%	+2.8%	+2.4%	+1.6%	+1.2%
Aug 11	Citigroup	Maintains	Buy → Buy	—	$12.02	$12.32	+2.5%	+3.5%	+8.3%	+16.0%	+19.0%	+19.5%
Jul 3	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$12.89	$12.96	+0.5%	+1.2%	+1.5%	+0.5%	+5.3%	+6.0%
Mar 10	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$12.00	$11.77	-1.9%	-7.5%	-2.5%	+2.3%	+4.6%	+2.1%
Mar 7	Citigroup	Maintains	Buy → Buy	—	$12.13	$12.21	+0.7%	-1.1%	-8.5%	-3.5%	+1.2%	+3.5%
Dec 19	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$12.74	$12.91	+1.3%	+6.6%	+11.0%	+12.1%	+11.0%	+13.8%
Dec 16	JP Morgan	Upgrade	Neutral → Overweight	—	$12.58	$13.47	+7.1%	+9.5%	+6.3%	+1.3%	+7.9%	+12.4%
Nov 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$13.68	$13.74	+0.4%	+4.5%	+3.8%	+4.5%	+5.4%	+3.0%
Nov 7	Leerink Partners	Upgrade	Market Perform → Outperform	—	$15.61	$16.37	+4.9%	+7.4%	+6.5%	+11.0%	+11.5%	+10.2%
Nov 4	Citigroup	Maintains	Buy → Buy	—	$13.28	$13.30	+0.2%	+11.1%	+10.4%	+17.5%	+26.3%	+25.2%
Nov 1	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$13.70	$12.77	-6.8%	-3.1%	+7.7%	+7.0%	+13.9%	+22.4%
Nov 1	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$13.70	$12.77	-6.8%	-3.1%	+7.7%	+7.0%	+13.9%	+22.4%
Oct 28	Stifel	Maintains	Buy → Buy	—	$12.93	$13.27	+2.6%	+2.4%	+6.0%	+7.3%	+6.0%	+2.7%
Aug 2	Stifel	Maintains	Buy → Buy	—	$10.11	$10.60	+4.8%	+0.9%	-1.1%	+0.4%	-2.8%	+0.9%
Jun 6	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.92	$8.99	+0.8%	+2.0%	+1.7%	+0.6%	+7.7%	+4.9%
May 7	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$9.06	$9.02	-0.4%	+0.7%	+0.0%	+1.9%	-2.8%	+2.0%
May 3	Citigroup	Maintains	Buy → Buy	—	$9.00	$8.84	-1.8%	+2.2%	+0.7%	+1.3%	+0.7%	+2.6%
May 3	Wells Fargo	Maintains	Overweight → Overweight	—	$9.00	$8.84	-1.8%	+2.2%	+0.7%	+1.3%	+0.7%	+2.6%
Mar 12	Wells Fargo	Maintains	Overweight → Overweight	—	$11.05	$11.15	+0.9%	-2.2%	-2.7%	-2.5%	-2.2%	-3.1%
Mar 11	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$11.44	$11.47	+0.3%	-3.4%	-5.5%	-6.0%	-5.9%	-5.5%
Aug 15	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$7.49	$7.47	-0.3%	-0.9%	-2.9%	-1.9%	-0.9%	+2.1%
Jun 6	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.94	$8.97	+0.3%	-1.5%	-0.6%	-2.3%	-4.7%	-6.5%
Jun 2	Citigroup	Maintains	Buy → Buy	—	$8.49	$8.50	+0.1%	+2.1%	+5.3%	+3.8%	+4.7%	+2.8%
May 18	Citigroup	Maintains	Buy → Buy	—	$9.19	$9.24	+0.5%	+4.4%	+6.3%	+0.0%	+0.2%	-4.2%
May 9	Stifel	Maintains	Buy → Buy	—	$8.76	$9.79	+11.8%	+12.8%	+10.6%	+13.9%	+12.6%	+12.1%
Mar 31	JP Morgan	Maintains	Neutral → Neutral	—	$8.76	$8.90	+1.6%	+3.2%	+7.0%	+7.3%	+7.4%	+7.2%
Mar 21	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.52	$8.61	+1.1%	+4.7%	-1.6%	-3.9%	-3.8%	-4.9%
Mar 10	Citigroup	Maintains	Buy → Buy	—	$8.08	$8.03	-0.6%	-1.9%	+2.1%	+4.8%	+6.8%	+2.7%
Mar 8	Guggenheim	Maintains	Buy → Buy	—	$7.96	$8.60	+8.0%	+0.5%	+1.5%	-0.4%	+3.6%	+6.4%
Jan 24	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$9.41	$9.87	+4.9%	+4.4%	+3.9%	+3.6%	+1.8%	+1.4%
Jan 20	SVB Leerink	Maintains	Market Perform → Market Perform	—	$9.68	$9.85	+1.8%	+3.3%	-2.8%	+1.4%	+1.0%	+0.7%
Jan 4	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$7.54	$7.63	+1.2%	+1.7%	+6.1%	+1.5%	+0.0%	+3.4%
Dec 22	Barclays	Maintains	Equal Weight → Equal Weight	—	$8.75	$8.75	+0.0%	+0.5%	-8.1%	-14.4%	-14.4%	-10.7%
Dec 20	Jefferies	Upgrade	Hold → Buy	—	$6.79	$7.07	+4.1%	+4.3%	+28.9%	+29.5%	+18.4%	+10.3%
Nov 21	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$7.76	$7.84	+1.0%	+2.4%	+0.0%	+3.6%	+1.0%	+0.9%
Nov 1	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$7.43	$7.26	-2.3%	+0.3%	-5.4%	-0.9%	+7.4%	+7.0%
Oct 24	Stifel	Maintains	Buy → Buy	—	$6.25	$6.15	-1.6%	-4.0%	-8.5%	-4.0%	-1.3%	+6.4%
Oct 21	SVB Leerink	Downgrade	Outperform → Market Perform	—	$6.45	$6.31	-2.2%	-3.1%	-7.0%	-11.3%	-7.0%	-4.3%
Sep 14	Citigroup	Maintains	Buy → Buy	—	$5.00	$4.94	-1.2%	-1.4%	+8.0%	+13.2%	+17.6%	+14.8%

Recent Filings

8-K

Unknown — 8-K Filing

ZYME's new Chief Financial Officer appointment signals potential leadership restructuring that investors should monitor for strategic direction changes and financial management quality improvements.

Apr 1

8-K

Zymeworks Inc. -- 8-K Filing

Zymeworks Inc. filed an 8-K providing updates under Items 2.02 and 7.01, though specific financial details or material events are not disclosed in this summary excerpt.

Mar 2

8-K · 1.01 ! Medium

Zymeworks Inc. -- 8-K 1.01: Financing / Debt Agreement

Zymeworks secured $250 million in royalty-backed financing through Zymeworks Royalty Limited Partners, providing capital to fund operations and development while leveraging future revenue streams.

Mar 2

Data updated apr 27, 2026 11:55am · Source: massive.com